Xingrong Zheng

Xingrong Zheng

Auto-generated profile, based on publicly available information

Xingrong Zheng

Department of Infectious Disease The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou Guangdong China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CXChan Xie
Chan Xie
XZXingrong Zheng
Xingrong Zheng
SHSongmin He
Songmin He
WXWenxiong Xu
Wenxiong Xu
WZWenbo Zhu
Wenbo Zhu
LPLiang Peng
Liang Peng
PURPOSE: This study evaluated the safety, tolerability, and preliminary efficacy of M1-c6v1, an oncolytic virus, combined with the immune checkpoint inhibitors (ICIs) camrelizumab and the vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor apatinib in advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: This single-arm, investigator-initiated, open-label clinical trial enrolled patients with advanced HCC (NCT04665362). Patients received M1-c6v1 (1×10⁹ CCID50) intravenously for 5 days every 28 days, camrelizumab (200 mg) intravenously biweekly, and apatinib (250 mg) orally daily. Treatment continued for up to 1 year or until disease progression, intolerability, or withdrawal. Primary endpoints were safety and tolerability, while secondary endpoints assessed efficacy based on tumor response, progression-free survival (PFS), and overall survival (OS). RESULTS: Thirteen patients were enrolled, with 84.6% having hepatitis B virus (HBV)-related HCC and 76.9% presenting with tumors >10 cm. The treatment was well-tolerated, with 92.15% of adverse events (AEs) being grade 1 or 2. The most common AEs included influenza-like symptoms and transient cytopenia. No viral shedding was detected in all secretions and excretions collected from subjects. In 10 patients evaluable for efficacy, the overall response rate (ORR) was 70% (7/10), with 7 partial responses (PR) according to mRECIST. The median OS and PFS was 15.4 and 8.9 months respectively. CONCLUSION: The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC.

15 October 2025
Verified
Other
Open access
CXChan Xie
Chan Xie
XZXingrong Zheng
Xingrong Zheng
SHSongmin He
Songmin He
WXWenxiong Xu
Wenxiong Xu
WZWenbo Zhu
Wenbo Zhu
LPLiang Peng
Liang Peng
Supplementary Figure 4. No positive viral copies were detected in 242 nasal swabs (3A), 242 urine samples (3B), and 108 stool samples (3C).

7 May 2026 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
QLQiumin Luo
Qiumin Luo
RXRuixuan Xu
Ruixuan Xu
YZYeqiong Zhang
Yeqiong Zhang
WXWenxiong Xu
Wenxiong Xu
XLXiangyong Li
Xiangyong Li
LPLiang Peng
Liang Peng
Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response. In this randomized controlled trial, HBeAg‐positive patients with normal ALT and elevated HBV DNA were randomly allocated 1:1 to receive TAF 25 mg/day or observation. The primary endpoint was the decline from baseline in HBsAg at Week 48. Secondary endpoints included HBV DNA response rates and the magnitude of HBV DNA reduction. The treatment group was further divided into virological response (VR) and low‐level viremia (LLV) subgroups based on HBV DNA response at Week 48. PBMCs from VR ( n = 3) and LLV ( n = 3) patients underwent scRNA‐seq for comparative immunological analysis. A total of 59 patients were allocated to the treatment ( n = 30) and control ( n = 29) groups. No serious adverse events occurred, except for one control patient who developed an ALT flare and required antiviral initiation. At Week 48, the treatment group demonstrated significantly greater reductions in HBsAg (0.19 vs. 0 log10 IU/mL, p = 0.005) and HBV DNA (6.32 vs. 0.19 log10 IU/mL, p < 0.001) compared to controls. In the treatment group, 20% achieved HBV DNA < 20 IU/mL and 3.3% achieved HBeAg seroconversion, while none occurred in the untreated patients. PBMCs scRNA‐seq revealed dominant distributions of NK_FCER1G, NK_KLRF1, NK_XCL1, and NKT_FCGR3A subclusters in the VR group, with upregulated expression of genes such as SLC27A4 and PTMA . Taken together, our findings revealed that TAF demonstrates favorable safety and antiviral efficacy in patients with high‐replicative, low‐inflammatory HBV infection during the 48‐week follow‐up period, although complete virological suppression rates remain suboptimal. NK‐mediated mechanisms may contribute to antiviral success. Trial Registration: The trial was registered on ClinicalTrials.gov (NCT 04231565).

15 October 2025
Verified
Other
Open access
CXChan Xie
Chan Xie
XZXingrong Zheng
Xingrong Zheng
SHSongmin He
Songmin He
WXWenxiong Xu
Wenxiong Xu
WZWenbo Zhu
Wenbo Zhu
LPLiang Peng
Liang Peng
Supplementary Figure 5. Neutralizing antibody (NAb) and its correlation with efficacy.

15 October 2025
Verified
Other
Open access
CXChan Xie
Chan Xie
XZXingrong Zheng
Xingrong Zheng
SHSongmin He
Songmin He
WXWenxiong Xu
Wenxiong Xu
WZWenbo Zhu
Wenbo Zhu
LPLiang Peng
Liang Peng
Purpose:This study evaluated the safety, tolerability, and preliminary efficacy of M1-c6v1, an oncolytic virus, combined with the immune checkpoint inhibitors camrelizumab and the VEGFR2 inhibitor apatinib in advanced hepatocellular carcinoma (HCC).Patients and Methods:This single-arm, investigator-initiated, open-label clinical trial enrolled patients with advanced HCC (NCT04665362). Patients received M1-c6v1 (9 × 108 cell culture infective dose 50%) intravenously for 5 days every 28 days, camrelizumab (200 mg) intravenously biweekly, and apatinib (250 mg) orally daily. Treatment continued for up to 1 year or until disease progression, intolerability, or withdrawal. Primary endpoints were safety and tolerability, and secondary endpoints assessed efficacy based on tumor response, progression-free survival, and overall survival.Results:Thirteen patients were enrolled, with 84.6% having hepatitis B virus–related HCC and 76.9% presenting with tumors >10 cm. The treatment was well tolerated, with 92.15% of adverse events being grade 1 or 2. The most common adverse events included influenza-like symptoms and transient cytopenia. No viral shedding was detected in all secretions and excretions collected from subjects. In 10 patients evaluable for efficacy, the overall response rate was 70% (7/10), with seven partial responses according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). The median overall survival and progression-free survival were 15.4 and 8.9 months, respectively.Conclusions:The combination of M1-c6v1 with camrelizumab and apatinib demonstrates an acceptable safety profile and promising efficacy in advanced HCC.

15 October 2025
Verified
Other
Open access
CXChan Xie
Chan Xie
XZXingrong Zheng
Xingrong Zheng
SHSongmin He
Songmin He
WXWenxiong Xu
Wenxiong Xu
WZWenbo Zhu
Wenbo Zhu
LPLiang Peng
Liang Peng
Supplementary Figure 2. Viral titer testing (CCID50/mL) from samples with positive viral RNA copies in serum.